Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury.

B. Zwissler, G. Kemming, Matthias Merkel, G. Wolfram, M. Kleen, O. Habler, M. Haller, J. Briegel

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND: A clinically relevant increase of PaO subset2 or decrease of pulmonary vascular resistance (PVR) upon inhalation of NO (iNO) does occur in only 60 to 80% of patients with acute lung injury. The mechanisms for divergent responses of different patients have not yet been fully elucidated. Since NO mediates its pulmonary effects by stimulating soluble guanylate cyclase, thereby increasing levels of cyclic guanosinemonophosphate (cGMP), we hypothesized that pulmonary cGMP production upon iNO might be suppressed in patients not responding to iNO treatment. METHODS: After approval by the local ethical committee and after informed consent had been obtained, both arterial and mixed-venous cGMP levels were analyzed in 13 patients in whom iNO was administered to treat pulmonary hypertension and/or hypoxemia due to acute respiratory distress syndrome (n = 11) or reperfusion injury following lung transplantation (n = 2). Both cardiorespiratory variables and cGMP concentrations were documented simultaneously at baseline, 15 min after inhalation of 8 ppm of NO, and 15 min after withdrawal of NO, respectively. RESULTS: Inhaled NO resulted in a significant increase in PaO(2)/FiO(2) and a decrease in PVR. Arterial and mixed venous concentration of cGMP (median) also increased significantly upon iNO from 2.5 to 6.5 nM (p

Original languageEnglish (US)
Pages (from-to)463-467
Number of pages5
JournalEuropean Journal of Medical Research
Volume4
Issue number11
StatePublished - Nov 22 1999
Externally publishedYes

Fingerprint

Acute Lung Injury
Inhalation
Nitric Oxide
Vascular Resistance
Lung
Lung Transplantation
Adult Respiratory Distress Syndrome
Reperfusion Injury
Informed Consent
Pulmonary Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury. / Zwissler, B.; Kemming, G.; Merkel, Matthias; Wolfram, G.; Kleen, M.; Habler, O.; Haller, M.; Briegel, J.

In: European Journal of Medical Research, Vol. 4, No. 11, 22.11.1999, p. 463-467.

Research output: Contribution to journalArticle

Zwissler, B, Kemming, G, Merkel, M, Wolfram, G, Kleen, M, Habler, O, Haller, M & Briegel, J 1999, 'Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury.', European Journal of Medical Research, vol. 4, no. 11, pp. 463-467.
Zwissler, B. ; Kemming, G. ; Merkel, Matthias ; Wolfram, G. ; Kleen, M. ; Habler, O. ; Haller, M. ; Briegel, J. / Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury. In: European Journal of Medical Research. 1999 ; Vol. 4, No. 11. pp. 463-467.
@article{80d408d816ea43798fcb19fac2f5fb0c,
title = "Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury.",
abstract = "BACKGROUND: A clinically relevant increase of PaO subset2 or decrease of pulmonary vascular resistance (PVR) upon inhalation of NO (iNO) does occur in only 60 to 80{\%} of patients with acute lung injury. The mechanisms for divergent responses of different patients have not yet been fully elucidated. Since NO mediates its pulmonary effects by stimulating soluble guanylate cyclase, thereby increasing levels of cyclic guanosinemonophosphate (cGMP), we hypothesized that pulmonary cGMP production upon iNO might be suppressed in patients not responding to iNO treatment. METHODS: After approval by the local ethical committee and after informed consent had been obtained, both arterial and mixed-venous cGMP levels were analyzed in 13 patients in whom iNO was administered to treat pulmonary hypertension and/or hypoxemia due to acute respiratory distress syndrome (n = 11) or reperfusion injury following lung transplantation (n = 2). Both cardiorespiratory variables and cGMP concentrations were documented simultaneously at baseline, 15 min after inhalation of 8 ppm of NO, and 15 min after withdrawal of NO, respectively. RESULTS: Inhaled NO resulted in a significant increase in PaO(2)/FiO(2) and a decrease in PVR. Arterial and mixed venous concentration of cGMP (median) also increased significantly upon iNO from 2.5 to 6.5 nM (p",
author = "B. Zwissler and G. Kemming and Matthias Merkel and G. Wolfram and M. Kleen and O. Habler and M. Haller and J. Briegel",
year = "1999",
month = "11",
day = "22",
language = "English (US)",
volume = "4",
pages = "463--467",
journal = "European Journal of Medical Research",
issn = "0949-2321",
publisher = "BioMed Central",
number = "11",

}

TY - JOUR

T1 - Response to inhaled nitric oxide (NO) is not associated with changes of plasma cGMP levels in patients with acute lung injury.

AU - Zwissler, B.

AU - Kemming, G.

AU - Merkel, Matthias

AU - Wolfram, G.

AU - Kleen, M.

AU - Habler, O.

AU - Haller, M.

AU - Briegel, J.

PY - 1999/11/22

Y1 - 1999/11/22

N2 - BACKGROUND: A clinically relevant increase of PaO subset2 or decrease of pulmonary vascular resistance (PVR) upon inhalation of NO (iNO) does occur in only 60 to 80% of patients with acute lung injury. The mechanisms for divergent responses of different patients have not yet been fully elucidated. Since NO mediates its pulmonary effects by stimulating soluble guanylate cyclase, thereby increasing levels of cyclic guanosinemonophosphate (cGMP), we hypothesized that pulmonary cGMP production upon iNO might be suppressed in patients not responding to iNO treatment. METHODS: After approval by the local ethical committee and after informed consent had been obtained, both arterial and mixed-venous cGMP levels were analyzed in 13 patients in whom iNO was administered to treat pulmonary hypertension and/or hypoxemia due to acute respiratory distress syndrome (n = 11) or reperfusion injury following lung transplantation (n = 2). Both cardiorespiratory variables and cGMP concentrations were documented simultaneously at baseline, 15 min after inhalation of 8 ppm of NO, and 15 min after withdrawal of NO, respectively. RESULTS: Inhaled NO resulted in a significant increase in PaO(2)/FiO(2) and a decrease in PVR. Arterial and mixed venous concentration of cGMP (median) also increased significantly upon iNO from 2.5 to 6.5 nM (p

AB - BACKGROUND: A clinically relevant increase of PaO subset2 or decrease of pulmonary vascular resistance (PVR) upon inhalation of NO (iNO) does occur in only 60 to 80% of patients with acute lung injury. The mechanisms for divergent responses of different patients have not yet been fully elucidated. Since NO mediates its pulmonary effects by stimulating soluble guanylate cyclase, thereby increasing levels of cyclic guanosinemonophosphate (cGMP), we hypothesized that pulmonary cGMP production upon iNO might be suppressed in patients not responding to iNO treatment. METHODS: After approval by the local ethical committee and after informed consent had been obtained, both arterial and mixed-venous cGMP levels were analyzed in 13 patients in whom iNO was administered to treat pulmonary hypertension and/or hypoxemia due to acute respiratory distress syndrome (n = 11) or reperfusion injury following lung transplantation (n = 2). Both cardiorespiratory variables and cGMP concentrations were documented simultaneously at baseline, 15 min after inhalation of 8 ppm of NO, and 15 min after withdrawal of NO, respectively. RESULTS: Inhaled NO resulted in a significant increase in PaO(2)/FiO(2) and a decrease in PVR. Arterial and mixed venous concentration of cGMP (median) also increased significantly upon iNO from 2.5 to 6.5 nM (p

UR - http://www.scopus.com/inward/record.url?scp=0033596015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033596015&partnerID=8YFLogxK

M3 - Article

C2 - 10585301

AN - SCOPUS:0033596015

VL - 4

SP - 463

EP - 467

JO - European Journal of Medical Research

JF - European Journal of Medical Research

SN - 0949-2321

IS - 11

ER -